The Low Density Lipoprotein Receptor Related Protein pipeline drugs market research report outlays comprehensive information on the Low Density Lipoprotein Receptor Related Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Low Density Lipoprotein Receptor Related Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Central Nervous System, Musculoskeletal Disorders, and Respiratory which include the indications Optic Nerve Injury, Diabetic Retinopathy, Alzheimer’s Disease, Multiple Sclerosis, Osteoporosis, Osteonecrosis, Idiopathic Pulmonary Fibrosis, and Acute Lung Injury. It also reviews key players involved in Low Density Lipoprotein Receptor Related Protein targeted therapeutics development with respective active and dormant or discontinued products.
The Low Density Lipoprotein Receptor Related Protein pipeline targets constitutes close to 18 molecules. Out of which, approximately 18 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 11, and 3 respectively.
Low Density Lipoprotein Receptor Related Protein overview
LRP is a protein forming a receptor in the cell plasma membrane, involved in receptor-mediated endocytosis. LRP is proteolytically processed by furin to generate subunits that form the mature receptor. This receptor is involved in several cellular processes, including intracellular signaling, lipid homeostasis, and clearance of apoptotic cells.
For a complete picture of Low Density Lipoprotein Receptor Related Protein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
